艾美疫苗(06660.HK)確認運營正常 上市前已發行H股禁售期屆滿
艾美疫苗(06660.HK)就股價及成交量不尋常波動聲明,確認集團的運營、財務和現有產品銷售情況均正常,且在研管線疫苗的研發均按計劃正常推進;及公司持有H股權益的董事均未出售或以其它方式處置所持H股。
同時,公司上市前已發行的H股一年禁售期已於10月6日屆滿。因此,10月9日為該等H股在聯交所開始流通交易的首日。
該股上交易日(9日)收報11.1元,下跌11.6元,跌幅51.1%;成交1,780萬股,成交額2.13億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.